J. P. Eder

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

D. P. Ryan, Jeffrey G. Supko, J. P. Eder et al. · PubMed · 2001 · 116 citations

Pharmacokinetic Study, Pathology, Pharmacotherapy +18

Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy

Lidia Schapira, JH Antin, BJ Ransil et al. · Blood · 1990 · 95 citations · Full text

Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.

Beverly A. Teicher, Sylvia A. Holden, J. P. Eder et al. · PubMed · 1989 · 66 citations

Multiple Injections, Immunology, Pharmacotherapy +18

A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients

Eric H. Rubin, Geoffrey I. Shapiro, Mark N. Stein et al. · Journal of Clinical Oncology · 2006 · 48 citations

Pathology, Pharmacotherapy, Cancer Patients +17

Phase I trial of escalating pentoxifylline dose with constant dose thiotepa.

Bruce J. Dezube, J. P. Eder, ArthurB. Pardee · PubMed · 1990 · 26 citations

Therapeutic Drug Monitoring, Pentoxifylline Dose, Drug Analysis +14